Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Genome profile of human rectal tumors and response to neoadjuvant chemoradiotherapy


ABSTRACT: Background: Neoadjuvant chemoradiotherapy (NCRT) is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies. Methods: Forty-eight candidates for NCRT were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade (TRG).Results: Both Smoothing and Hidden Markov Model (HMM) approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number of genome changes mainly located on 2q21, 7q21, 7q36, 13q12, 13q32-34, 16p13, 17p12 chromosomal regions. Conclusion: This exploratory study suggests that an in depth characterization of chromosomal alterations by aCGH would provide useful predictive information about response to NCRT and help to optimize therapy in rectal cancer patients. 48 samples included in the study were analyzed on whole genome BAC arrays with the aim to characterize genomic alterations and correlate them with the tumor response to therapy. The case series was composed by 15%,81% and 4% of uT2, uT3 and uT4 tumors, respectively. At the diagnosis 56% of patients had uN0 tumors and 44% uN+. 30%,13%, 23% and 34% of patients reached/mantained respectively ypT0, ypT1, ypT2 and ypT3. With regard to response to NCRT, according to TRG criteria proposed by Dworak, two group were defined: non responders (TRG0-2= 56%) and responders (TRG3-4=44%). Clinical and pathological parameters: uT: pre-therapy stage determined by ultrasounds techniques uN: pre-therapy lymph node status determined by ultrasounds techniques ypT: pathologic stage after a neoadjuvant treatment ypN: pathologic lymph node status after a neoadjuvant treatment

ORGANISM(S): Homo sapiens

SUBMITTER: Chiara Molinari 

PROVIDER: E-GEOD-25885 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.

Molinari Chiara C   Ballardini Michela M   Teodorani Nazario N   Giannini Massimo M   Zoli Wainer W   Emiliani Ermanno E   Lucci Enrico E   Passardi Alessandro A   Rosetti Paola P   Saragoni Luca L   Guidoboni Massimo M   Amadori Dino D   Calistri Daniele D  

Radiation oncology (London, England) 20111118


<h4>Background</h4>Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies.<h4>Methods</h4>Forty-eight candidates for neoadjuvant chemoradiothe  ...[more]

Similar Datasets

2011-11-17 | GSE25885 | GEO
2012-04-24 | E-GEOD-29298 | biostudies-arrayexpress
2016-04-21 | GSE65622 | GEO
2012-04-25 | GSE29298 | GEO
2020-02-22 | GSE145666 | GEO
2023-03-11 | PXD023302 | Pride
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress
2021-09-08 | PXD013431 | Pride
2014-01-03 | E-GEOD-53781 | biostudies-arrayexpress